Comparison of standardised versus non-standardised methods for testing the in vitro potency of oxytetracycline against mannheimia haemolytica and pasteurella multocida [PDF]
, 2016 The in vitro pharmacodynamics of oxytetracycline was established for six isolates of each of the calf pneumonia pathogens Mannheimia haemolytica and Pasteurella multocida.
Aliabadi +26 more
core +4 more sources
Structure of anhydrotetracycline-bound Tet(X6) reveals the mechanism for inhibition of type 1 tetracycline destructases [PDF]
, 2023 Inactivation of tetracycline antibiotics by tetracycline destructases (TDases) remains a clinical and agricultural threat. TDases can be classified as type 1 Tet(X)-like TDases and type 2 soil-derived TDases.
Blake, Kevin S +6 more
core +2 more sources
Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida [PDF]
, 2017 Pharmacokinetic–pharmacodynamic (PK/PD) integration and modelling were used to predict dosage schedules of oxytetracycline for two pig pneumonia pathogens, Actinobacillus pleuropneumoniae and Pasteurella multocida.
Aliabadi +34 more
core +2 more sources
Factors influencing the potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida [PDF]
, 2017 For the pig respiratory tract pathogens, Actinobacillus pleuropneumoniae and Pasteurella multocida, Minimum Inhibitory Concentration (MIC) of marbofloxacin was determined in recommended broths and pig serum at three inoculum strengths.
Dorey, L, Hobson, S, Lees, P
core +2 more sources
Advances in antibiotic therapy in the critically ill [PDF]
, 2016 Infections occur frequently in critically ill patients and their management can be challenging for various reasons, including delayed diagnosis, difficulties identifying causative microorganisms, and the high prevalence of antibiotic-resistant strains ...
Antonelli, Massimo +13 more
core +2 more sources
New Antibiotics for Staphylococcus aureus Infection: An Update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-Infective Therapy (SITA) [PDF]
, 2023 Staphylococcus aureus is an extremely virulent pathogen that is capable of quickly evolving and developing antibiotic resistance. To overcome this problem, new antibiotics have been developed.
Bassetti M. +11 more
core +4 more sources
Antibiotics, 2021 Introduction: Approximately 3% of hospitalized patients with community-acquired bacterial pneumonia (CABP) develop healthcare-associated Clostridioides difficile infection (HCA-CDI). The validated Davis risk score (DRS) indicates that patients with a DRS
Thomas Lodise +4 more
doaj +1 more source
Targeting antibiotic resistance [PDF]
, 2016 Finding strategies against the development of antibiotic resistance is a major global challenge for the life sciences community and for public health.
Chellat, Mathieu F. +2 more
core +1 more source
Omadacycline: a novel aminomethylcycline.
Infection and drug resistance, 2019 Tetracyclines have come a long way since they became available almost seven decades ago, with numerous enhancements allowing new agents to overcome bacterial mechanisms of resistance. However, these enhancements come with toxicities and pharmacokinetic disadvantages such as the gastrointestinal side-effects and poor oral bioavailability seen with the ...
Burgos,Rodrigo M, Rodvold,Keith A
openaire +5 more sources
Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia
International Journal of Infectious Diseases, 2021 Objective: Community-acquired bacterial pneumonia (CABP) is a major clinical burden worldwide. In the phase III OPTIC study (NCT02531438) in CABP, omadacycline was found to be non-inferior to moxifloxacin for investigator-assessed clinical response (IACR)
Antoni Torres +9 more
doaj +1 more source